標(biāo)題: Titlebook: Clinical Pharmacology: Current Topics and Case Studies; Markus Müller Book 2016Latest edition Springer International Publishing Switzerlan [打印本頁(yè)] 作者: 厭倦了我 時(shí)間: 2025-3-21 18:28
書(shū)目名稱Clinical Pharmacology: Current Topics and Case Studies影響因子(影響力)
書(shū)目名稱Clinical Pharmacology: Current Topics and Case Studies影響因子(影響力)學(xué)科排名
書(shū)目名稱Clinical Pharmacology: Current Topics and Case Studies網(wǎng)絡(luò)公開(kāi)度
書(shū)目名稱Clinical Pharmacology: Current Topics and Case Studies網(wǎng)絡(luò)公開(kāi)度學(xué)科排名
書(shū)目名稱Clinical Pharmacology: Current Topics and Case Studies被引頻次
書(shū)目名稱Clinical Pharmacology: Current Topics and Case Studies被引頻次學(xué)科排名
書(shū)目名稱Clinical Pharmacology: Current Topics and Case Studies年度引用
書(shū)目名稱Clinical Pharmacology: Current Topics and Case Studies年度引用學(xué)科排名
書(shū)目名稱Clinical Pharmacology: Current Topics and Case Studies讀者反饋
書(shū)目名稱Clinical Pharmacology: Current Topics and Case Studies讀者反饋學(xué)科排名
作者: 煩人 時(shí)間: 2025-3-22 00:02
Clinical Pharmacology: Current Topics and Case Studies978-3-319-27347-1作者: sebaceous-gland 時(shí)間: 2025-3-22 02:07
Current Issues in Drug Development specific kinase inhibitors. Whereas success rates in (1) and (2) are determined by a combination of powerful drugs which were rapidly developed by industry in response to the challenge posed by the HIV and HCV pandemics, success rates in (3) are determined by the discovery of an entirely new and/or作者: 草率女 時(shí)間: 2025-3-22 04:52 作者: 節(jié)約 時(shí)間: 2025-3-22 10:54 作者: FLUSH 時(shí)間: 2025-3-22 15:12 作者: FLUSH 時(shí)間: 2025-3-22 20:51
Pharmacokinetics II: 14C-Labelled Microdosing in Assessing Drug Pharmacokinetics at Phase 0to interpret the microdose data in the context of the selection of candidate drugs for further development. Inclusion of a .C isotopic tracer into the molecule enables sensitive AMS analysis to be used, obtaining an early indication of the drug’s metabolism in humans.作者: Psa617 時(shí)間: 2025-3-22 23:00
Current Concepts of Pharmacogenetics, Pharmacogenomics, and the “Druggable” Genomeever, still lie ahead until genomic medicine will find its place in routine clinical practice. In this chapter, important facts of the principles in genomic medicine are summarized, providing insight into ways how genetic information of an individual can be used to improve drug safety and efficacy a作者: brother 時(shí)間: 2025-3-23 03:24 作者: SPECT 時(shí)間: 2025-3-23 08:40 作者: 表被動(dòng) 時(shí)間: 2025-3-23 13:36
Margareta Stefanovic,Michael G. Safonov specific kinase inhibitors. Whereas success rates in (1) and (2) are determined by a combination of powerful drugs which were rapidly developed by industry in response to the challenge posed by the HIV and HCV pandemics, success rates in (3) are determined by the discovery of an entirely new and/or作者: 法官 時(shí)間: 2025-3-23 15:20 作者: lacrimal-gland 時(shí)間: 2025-3-23 21:07 作者: Awning 時(shí)間: 2025-3-24 00:12
Ken Chan,Clive Fencott,Barry Hebbronovide a false sense of security and apparent safety if there is little inter-species cross-reactivity for an antibody or if the response pattern may be highly specific for humans. Clinical pharmacologists with a strong scientific background in the particular field of science should play a key role a作者: cinder 時(shí)間: 2025-3-24 03:30 作者: 條約 時(shí)間: 2025-3-24 07:13
Modeling Fault Trees Using Petri Netsever, still lie ahead until genomic medicine will find its place in routine clinical practice. In this chapter, important facts of the principles in genomic medicine are summarized, providing insight into ways how genetic information of an individual can be used to improve drug safety and efficacy a作者: d-limonene 時(shí)間: 2025-3-24 11:21
https://doi.org/10.1007/978-1-4471-0937-2PK exposure parameters to microbiological outcomes, clinicians have designed better dosing strategies for specific classes of antibiotics. By evaluating how covariates affect the drug disposition in specific patient population, dosing regimens can be designed for that population to achieve an optima作者: 態(tài)學(xué) 時(shí)間: 2025-3-24 18:31 作者: bacteria 時(shí)間: 2025-3-24 22:27 作者: mighty 時(shí)間: 2025-3-25 00:25
Book 2016Latest editionegulatory issues. In addition, in-depth insights into clinical drug research and trial methodology are presented on the basis of concrete case studies. This updated book makes a valuable contribution to the field of Clinical Pharmacology and serves as a must-have guide for professors, researchers an作者: 為寵愛(ài) 時(shí)間: 2025-3-25 05:20 作者: bleach 時(shí)間: 2025-3-25 07:51
Margareta Stefanovic,Michael G. Safonoveny marketing authorisation where deemed necessary. By contrast, the second objective requires regulators to support and enable drug development – with a view to ensuring that patients have access as early as possible to safe and effective drugs.作者: 心胸狹窄 時(shí)間: 2025-3-25 12:11 作者: phlegm 時(shí)間: 2025-3-25 16:25
Margareta Stefanovic,Michael G. Safonovy administering appropriate drug therapy to patients; and (c) within a regulatory framework, to provide guidance on the risk/benefit ratio of drug candidates in drug development and drug reimbursement.作者: 無(wú)表情 時(shí)間: 2025-3-25 20:10
Modeling Fault Trees Using Petri Netshed tools, whereas optical imaging (fluorescence) is a novel and promising one. Structural morphology of organs or tissues can be investigated with anatomical techniques such as ultrasound imaging, X-ray, X-ray computed tomography (CT) and magnetic resonance imaging (MRI).作者: 委派 時(shí)間: 2025-3-26 00:48
The Discipline of Clinical Pharmacologyy administering appropriate drug therapy to patients; and (c) within a regulatory framework, to provide guidance on the risk/benefit ratio of drug candidates in drug development and drug reimbursement.作者: 助記 時(shí)間: 2025-3-26 07:03 作者: packet 時(shí)間: 2025-3-26 09:25 作者: 截?cái)?nbsp; 時(shí)間: 2025-3-26 14:55 作者: 手銬 時(shí)間: 2025-3-26 20:48 作者: Oration 時(shí)間: 2025-3-27 00:05
Amer Saeed,Rogério de Lemos,Tom Andersonign types are available. These study design types share a number of common methodological principles, and they all will always include some degree of random error, bias, and confounding. In this chapter we will illustrate design principles, practical applicability, limitations, and discuss critical appraisal of observational studies.作者: deforestation 時(shí)間: 2025-3-27 03:35 作者: 尊重 時(shí)間: 2025-3-27 06:45 作者: 臆斷 時(shí)間: 2025-3-27 10:31 作者: 繁忙 時(shí)間: 2025-3-27 14:09
https://doi.org/10.1007/978-3-319-27347-1drug development; clinical trial; gene therapy; kinetics; pharmacodynamics; drug research; pharmacotherapy作者: Rejuvenate 時(shí)間: 2025-3-27 19:27
978-3-319-80118-6Springer International Publishing Switzerland 2016作者: 開(kāi)頭 時(shí)間: 2025-3-27 23:35
Observational Studiesign types are available. These study design types share a number of common methodological principles, and they all will always include some degree of random error, bias, and confounding. In this chapter we will illustrate design principles, practical applicability, limitations, and discuss critical appraisal of observational studies.作者: 交響樂(lè) 時(shí)間: 2025-3-28 05:14 作者: 殘暴 時(shí)間: 2025-3-28 09:03
A. J. Harrison,I. D. R. ShannonGood clinical practice (GCP) is an international ethical and scientific quality standard for designing, conducting, recording and reporting trials that involve human subjects.作者: 召集 時(shí)間: 2025-3-28 12:51
Good Clinical Practice (GCP) and Scientific MisconductGood clinical practice (GCP) is an international ethical and scientific quality standard for designing, conducting, recording and reporting trials that involve human subjects.作者: Confound 時(shí)間: 2025-3-28 16:02
Margareta Stefanovic,Michael G. Safonovand that “drug therapy varies widely among individuals” [.]. These two statements set the stage for the discipline of clinical pharmacology (CP) which pursues two main goals: (1) an empirical description of conditions under which drug actions vary in humans and (2) to determine and understand the mo作者: 沙文主義 時(shí)間: 2025-3-28 20:33
Margareta Stefanovic,Michael G. Safonoves, most notably infections, have extremely satisfying therapeutic success rates, and many serious diseases like diabetes mellitus or some forms of cancer have become chronic, stable diseases and do not lead to extreme shortages of life years any longer. Prime examples for success stories in drug de作者: antecedence 時(shí)間: 2025-3-29 00:38 作者: climax 時(shí)間: 2025-3-29 04:27 作者: Ablation 時(shí)間: 2025-3-29 09:45 作者: 名次后綴 時(shí)間: 2025-3-29 14:01
Ken Chan,Clive Fencott,Barry Hebbronessively establish their safety and ultimately their efficacy. Disasters occur only rarely during phase I trials, which have a remarkable safety record. In 2006, a contract research organization was conducting the first human testing of TGN1412 an immunomodulatory anti-CD28 monoclonal antibody. All 作者: 轎車 時(shí)間: 2025-3-29 19:36 作者: Pituitary-Gland 時(shí)間: 2025-3-29 20:30 作者: Corroborate 時(shí)間: 2025-3-30 03:06 作者: acheon 時(shí)間: 2025-3-30 07:34
Legal Aspects of Safety Critical Systemse the number of compounds where the pharmacokinetics observed at a microdose compared to a therapeutic dose has grown steadily. Based upon the most up-to-date review at the time of writing (2013, reference Lappin et al., Expert Opin Drug Metab Toxicol 9(7):817–834, 2013), there are 35 compounds wher作者: Arthropathy 時(shí)間: 2025-3-30 11:46
Modeling Fault Trees Using Petri Netsity will be translated into clinical practice. According to the current intriguing concepts of pharmacogenetics and pharmacogenomics, genetic information of individuals can be used to avoid “trial and error” scenarios during medication. Based on evidence from genomic testing, medicine is expected to作者: 撤退 時(shí)間: 2025-3-30 16:15
https://doi.org/10.1007/978-1-4471-0937-2te of infection for a sufficient amount of time that would stop the development of bacterial resistance and on the susceptibility and severity of the infection. Therapeutic success of therapy is also dependent on the physiological characteristics of the host, including disease state, age, comorbidit作者: 親屬 時(shí)間: 2025-3-30 16:37
Hans-Peter Meske,Wolfgang A. Halangnd consequences of diseases. The following chapter will give the reader a brief overview on how epidemiological data are gained and analyzed. Furthermore, the chapter will briefly cover the importance of biostatistics in the interpretation of study data as well as possible pitfalls.作者: 鳴叫 時(shí)間: 2025-3-30 22:08 作者: 巧辦法 時(shí)間: 2025-3-31 04:32 作者: chapel 時(shí)間: 2025-3-31 08:59
Current Issues in Drug Developmentes, most notably infections, have extremely satisfying therapeutic success rates, and many serious diseases like diabetes mellitus or some forms of cancer have become chronic, stable diseases and do not lead to extreme shortages of life years any longer. Prime examples for success stories in drug de作者: anaphylaxis 時(shí)間: 2025-3-31 10:43
Current Issues in Drug Regulationjectives: first, into an obligation to protect patients against ineffective or harmful drugs and, second, to protect patients against the consequences of untreated disease. The first objective results in a gatekeeper function and obliges regulators to apply stringent standards of assessment and to d作者: narcissism 時(shí)間: 2025-3-31 13:39
